

FORM 9

[NOTE: This Form 9 corrects the Form 9 filed on September 14, 2017.]

NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES **(or securities convertible or exchangeable into listed securities¹)**

Please complete the following:

Name of CNSX Issuer: WESTERN URANIUM CORPORATION (the "Issuer").

Trading Symbol: WUC.

Date: November 15, 2017.

Is this an updating or amending Notice: Yes No

If yes provide date(s) of prior Notices: September 12, 2017 and September 14, 2017.

Issued and Outstanding Securities of Issuer Prior to Issuance: 19,574,709.

Date of News Release Announcing Private Placement: N/A.

Closing Market Price on Day Preceding the Issuance of the News Release: N/A

(The Issuer was granted price protection by the CSE on July 20, 2017 based on the July 19, 2017 closing price of CAD\$1.04 per share. An extension was granted by the CSE on August 21, 2017.)

1. Private Placement (if shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition), proceed to Part 2 of this form)

Full Name & Residential Address of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable)	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed (Prior to Completion of Private Placement)	Payment Date(1)	Describe relationship to Issuer (2)
J. Dienner Pennsylvania, USA	15,000	\$0.90	N/A	Securities Act of 1933, s.4(2) (USA)	15,000	On or before September 12, 2017	N/A

J. Zook Pennsylvania, USA	20,000	\$0.90	N/A	Securities Act of 1933, s.4(2) (USA)	11,429	On or before September 11, 2017	N/A
D. Zook Pennsylvania, USA	50,000	\$0.90	N/A	Securities Act of 1933, s.4(2) (USA)	28,571	On or before September 11, 2017	N/A
S. Wright Utah, USA	25,000	\$0.90	N/A	Securities Act of 1933, s.4(2) (USA)	11,000	On or before September 11, 2017	N/A
T. LePouttre Belgium	8,000	\$0.90	N/A	Foreign Subscriber	Nil	September 13, 2017	N/A
D. Morningstar Ontario, Canada	10,000	\$0.90	N/A	NI 45-106 s. 2.3 (Canada)	Nil	September 13, 2017	N/A
M. Bigger New York, USA	70,000	\$0.90	N/A	Securities Act of 1933, s.4(2) (USA)	Nil	September 13, 2017	N/A
C. Taylor Alberta, Canada	7,100	\$0.90	N/A	NI 45-106 s. 2.3 (Canada)	30,400	On or before September 11, 2017	N/A
A. Chen California, USA	27,777	\$0.90	N/A	Securities Act of 1933, s.4(2) (USA)	18,877	On or before September 11, 2017	N/A
R. Bignold Argentina	8,886	\$0.90	N/A	Foreign Subscriber	5,714	September 13, 2017	N/A
N. Pantelis Curaçao	15,000	\$0.90	N/A	Foreign Subscriber	Nil	September 13, 2017	N/A
M. Zook Pennsylvania, USA	20,000	\$0.90	N/A	Securities Act of 1933, s.4(2) (USA)	Nil	On or before September 11, 2017	N/A

R. Kettell Guatemala	6,000	\$0.90	N/A	Foreign Subscriber	Nil	September 13, 2017	N/A
A. Kuznecov British Columbia, Canada	12,000	\$0.90	N/A	NI 45-106 s. 2.3 (Canada)	Nil	September 13, 2017	N/A
S. McCarthy British Columbia, Canada	7,500	\$0.90	N/A	NI 45-106 s. 2.3 (Canada)	Nil	September 13, 2017	N/A
K. Myland British Columbia, Canada	7,500	\$0.90	N/A	NI 45-106 s. 2.3 (Canada)	10,000	September 13, 2017	N/A
H. Addison British Columbia, Canada	135,000	\$0.90	N/A	NI 45-106 s. 2.3 (Canada)	205,000	September 13, 2017	N/A
N. Selby British Columbia, Canada	15,000	\$0.90	N/A	NI 45-106 s. 2.3 (Canada)	60,000	September 13, 2017	N/A
R. or B. D'Angela Ontario, Canada	50,000	\$0.90	N/A	NI 45-106 s. 2.3 (Canada)	100,000	September 14, 2017	N/A

(1) Indicate date each placee advanced or is expected to advance payment for securities. Provide details of expected payment date, conditions to release of funds etc. Indicate if the placement funds been placed in trust pending receipt of all necessary approvals.

(2) Indicate if Related Person.

¹An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: Cdn\$458,786.70 .
2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material. The proceeds of the Private Placement will be utilized to fund the Company's resource holding, working capital, and advancement of ablation technology.
3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: N/A.

4. If securities are issued in forgiveness of indebtedness, provide details and attach the debt agreement(s) or other documentation evidencing the debt and the agreement to exchange the debt for securities.

5. Description of securities to be issued:

(a) Class COMMON SHARES .

(b) Number 509,763 .

(c) Price per security Cdn \$0.90 .

(d) Voting rights YES .

6. Provide the following information if Warrants, (options) or other convertible securities are to be issued: Each full common share purchase warrant shall entitle the holder to purchase one common share at the exercise price of Cdn\$1.40 for a term of five (5) years from the closing date of the offering.

(a) Number 509,763 warrants .

(b) Number of securities eligible to be purchased on exercise of Warrants (or options) 509,763 common shares .

(c) Exercise price Cdn\$1.40 per common share .

(d) Expiry date Five (5) years after the issuance date.

7. Provide the following information if debt securities are to be issued: N/A

(a) Aggregate principal amount _____ .

(b) Maturity date _____ .

(c) Interest rate _____ .

(d) Conversion terms _____ .

(e) Default provisions _____ .

8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):

(a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer):

The persons receiving compensation in connection with this private placement are as follows:

- Canaccord Genuity Corp. having its address in Toronto, Canada;
- Leede Jones Gable Inc. having its address in Vancouver, Canada;
- Haywood Securities Inc. having its address in Vancouver, Canada; and
- PI Financial Corp. having its address in Vancouver, Canada.

The Issuer does not know who are the persons owning or exercising voting control over 20% or more of the voting shares of the above finders.

(b) Cash The fees paid in connection to this private placement are as follows:

- Canaccord Genuity Corp. – Cdn\$5,760;
- Leede Jones Gable Inc. – Cdn\$11,880;
- Haywood Securities Inc. – Cdn\$639.79; and
- PI Financial Corp. – Cdn\$1,296.

(c) Securities The broker warrants issued in connection to this private placement are as follows:

- Canaccord Genuity Corp. – 6,400 broker warrants;
- Leede Jones Gable Inc. – 13,200 broker warrants;
- Haywood Securities Inc. – 711 broker warrants;
- PI Financial Corp. – 1,440 broker warrants; and

These broker warrants are exercisable at a price of Cdn\$1.40 per common share for a period of 24 months from the closing date of the offering.

(d) Other N/A .

(e) Expiry date of any options, warrants etc. Two (2) years after the issuance date. .

(f) Exercise price of any options, warrants etc. Cdn\$1.40 per common share.

9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship

The persons receiving compensation in connection with this private placement are not related to the issuer.

10. Describe any unusual particulars of the transaction (i.e. tax “flow through” shares, etc.).

N/A _____ .

11. State whether the private placement will result in a change of control.

N/A _____ .

12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. N/A _____

_____ .

13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by Multilateral Instrument 45-102.

2. Acquisition – N/A

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: _____
_____ .

2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material: _____
_____ .

3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:

(a) Total aggregate consideration in Canadian dollars: _____ .

(b) Cash: _____ .

(c) Securities (including options, warrants etc.) and dollar value: _____
_____ .

(d) Other: _____ .

(e) Expiry date of options, warrants, etc. if any: _____ .

(f) Exercise price of options, warrants, etc. if any: _____ .

(g) Work commitments: _____ .

4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc).
5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: _____
_____ .
6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed by Party	Describe relationship to Issuer⁽¹⁾

(1) Indicate if Related Person

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: _____
_____ .
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.):
 - (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): _____
_____ .
 - (b) Cash _____ .
 - (c) Securities _____ .
 - (d) Other _____ .
 - (e) Expiry date of any options, warrants etc. _____ .
 - (f) Exercise price of any options, warrants etc. _____ .

9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. _____

10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. _____

_____ .

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 9 Notice of Private Placement is true.

Dated November 15, 2017.

Robert R. Klein
Name of Director or Senior
Officer

/s/ Robert R. Klein
Signature

Chief Financial Officer
Official Capacity